Arvinas Inc (NAS:ARVN)
$ 33.9 -1.35 (-3.83%) Market Cap: 2.32 Bil Enterprise Value: 1.25 Bil PE Ratio: 0 PB Ratio: 3.80 GF Score: 66/100

Arvinas Inc ASCO Data Conference Call Transcript

May 29, 2020 / 12:30PM GMT
Release Date Price: $33.27 (-25.82%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to the Arvinas ASCO Data conference call. At this time, all participant lines are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. (Operator Instructions). Please be advised that today's conference may be recorded. I would now like to hand the conference over to your speaker today, Mr. Randy Teel, Vice President, Corporate Development. Sir, you may begin.

Randy Teel
Arvinas - V.P. Corporate Development

Thank you. Good morning, everyone, and thank you for joining us today for an interim review of clinical data for androgen receptor degrading PROTAC protein degrader ARV-110, which was released this morning as oral abstract presentation at the 2020 ASCO Annual Meeting.

You can access the relative press release, 8K filing and the slides for today's presentation in the Investor section of our Web site at www.arvinas.com. This webcast will be audio only but it's designed that you can

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot